Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice.
about
PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical modelsEmerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cellsIncorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells.A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer.Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors.Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.Prostate stem cell antigen variation rs2294008 associated with the risk of bladder cancer.Making Better Chimeric Antigen Receptors for Adoptive T-cell TherapyToxicities of chimeric antigen receptor T cells: recognition and management.CAR T-cell therapy: toxicity and the relevance of preclinical models.Novel PSCA targeting scFv-fusion proteins for diagnosis and immunotherapy of prostate cancer.Adoptive T-Cell Therapy for Solid Tumors.Immune Therapy for Prostate Cancer.The Multi-Purpose Tool of Tumor Immunotherapy: Gene-Engineered T Cells.Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome.Exploratory investigation of PSCA-protein expression in primary breast cancer patients reveals a link to HER2/neu overexpression.Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer.PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells.Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model.
P2860
Q27339832-37D6E74D-102B-4CC8-8745-6C83F23B2536Q33833475-DC330307-FF13-4DF6-8DAB-45F0D83B4029Q34553167-D4B16EC2-30C4-4552-AFA2-08FE44F47986Q34729692-9724741D-F07F-4465-B08A-9EA948F32CE9Q35877585-37035BAD-E753-494B-91FD-734FC5532C3DQ35980893-12B7D952-C45A-4C16-AA3C-A8209C7C12F4Q36182999-0D1AE6E9-C1C8-42A8-B43A-04615D3EA42CQ36830759-6803E41D-C42D-4D22-A8BE-50284136F639Q37058104-9804A2C7-EAC4-4DA5-A81F-99EF87E911CAQ38525018-684D4916-9A02-4699-B0C2-430558067CC6Q38699173-867A7281-86AB-4A1E-90D9-A64BD4F1B293Q38754498-EC6B7D57-7051-4AEE-970A-8926D1BB702DQ38982667-20084C7D-13F4-482D-A87C-3DCC8E8560C5Q40095245-015864C5-B970-4011-AF0E-F479B897FF37Q41298215-BC90D755-7197-4751-BA48-4FCA5E4AEEC8Q41551352-EA5430FF-5936-4132-955B-A5ADFFC276DAQ47129409-73B0186F-8E14-4202-9CC1-3CD7248E6F30Q47920923-0993A33B-FB49-4674-9759-C6DCB2289475Q55322285-23BF1313-F8AF-4369-B300-7777B44A86A4
P2860
Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Systemic treatment with CAR-en ...... and prolongs survival of mice.
@en
Systemic treatment with CAR-en ...... and prolongs survival of mice.
@nl
type
label
Systemic treatment with CAR-en ...... and prolongs survival of mice.
@en
Systemic treatment with CAR-en ...... and prolongs survival of mice.
@nl
prefLabel
Systemic treatment with CAR-en ...... and prolongs survival of mice.
@en
Systemic treatment with CAR-en ...... and prolongs survival of mice.
@nl
P2093
P2860
P356
P1433
P1476
Systemic treatment with CAR-en ...... and prolongs survival of mice.
@en
P2093
Justyna Leja
Magnus Essand
Mohanraj Ramachandran
Victoria Hillerdal
P2860
P2888
P356
10.1186/1471-2407-14-30
P407
P577
2014-01-18T00:00:00Z
P5875
P6179
1048975532